
Jiuliang Zhao

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2063762/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Sirolimus versus tacrolimus for systemic lupus erythematosus treatment: results from a real-world CSTAR cohort study. Lupus Science and Medicine, 2022, 9, e000617.	2.7	8
2	The role of anti-ribosomal P autoantibodies in the prediction of neuropsychiatric damage in systemic lupus erythematosus based on CSTAR cohort (XIV). Clinical Rheumatology, 2022, 41, 1371-1379.	2.2	3
3	CD127 imprints functional heterogeneity to diversify monocyte responses in inflammatory diseases. Journal of Experimental Medicine, 2022, 219, .	8.5	21
4	Characteristics and risk factors of retinal vasculopathy in antiphospholipid syndrome. Lupus, 2022, 31, 178-186.	1.6	1
5	Detection of IgA Antiphospholipid Antibodies Does not Improve Thrombotic Antiphospholipid Syndrome Classification: A two-Center Study. Clinical and Applied Thrombosis/Hemostasis, 2022, 28, 107602962210811.	1.7	3
6	Impact of pregnancy in patients with systemic lupus erythematosus-associated pulmonary arterial hypertension: case series and literature review. Lupus Science and Medicine, 2022, 9, e000636.	2.7	2
7	The challenges and future perspective for the management of systemic lupus erythematosus in China: A concise annual report of 2020. Rheumatology and Immunology Research, 2022, 3, 38-44.	0.8	2
8	Effects of conventional rehabilitative and aerobic training in patients with idiopathic inflammatory myopathy. Rheumatology and Immunology Research, 2022, 3, 23-30.	0.8	1
9	Prognostic factors of systemic lupus erythematosus patients with pulmonary embolism: An 11-year cohort study. Lupus, 2022, 31, 885-890.	1.6	3
10	The treatment strategy of connective tissue disease associated pulmonary arterial hypertension: Evolving into the future. , 2022, 239, 108192.		7
11	Thrombocytopenia in primary antiphospholipid syndrome: association with prognosis and clinical implications. Rheumatology, 2022, 62, 256-263.	1.9	11
12	Right Ventricle to Pulmonary Artery Coupling Predicts the Risk Stratification in Patients With Systemic Sclerosis-Associated Pulmonary Arterial Hypertension. Frontiers in Cardiovascular Medicine, 2022, 9, .	2.4	1
13	Pregnancy outcomes in Takayasu arteritis patients. Seminars in Arthritis and Rheumatism, 2022, 55, 152016.	3.4	5
14	Implementation of the treat-to-target approach and treatment satisfaction in patients with rheumatoid arthritis: perspectives of Chinese rheumatologists. Clinical Rheumatology, 2022, 41, 2659-2668.	2.2	1
15	Exploring the risk factors and prognosis of transverse myelitis in systemic lupus erythematosus. Therapeutic Advances in Chronic Disease, 2022, 13, 204062232210973.	2.5	2
16	Immunosuppressive therapy in patients with connective tissue diseaseâ€associated pulmonary arterial hypertension: A systematic review. International Journal of Rheumatic Diseases, 2022, 25, 982-990.	1.9	7
17	Dorsolateral medullary infarction during skin infection by Stenotrophomonas maltophilia in a patient with triple antiphospholipid antibody positivity: a case-based review. Clinical Rheumatology, 2021, 40, 2965-2971.	2.2	2
18	Clinical characteristics and prognosis of concomitant systemic lupus erythematosus and primary biliary cholangitis. Clinical Rheumatology, 2021, 40, 1819-1826.	2.2	5

#	Article	IF	CITATIONS
19	Relationship between disease activity, organ damage and health-related quality of life in patients with systemic lupus erythematosus: A systemic review and meta-analysis. Autoimmunity Reviews, 2021, 20, 102691.	5.8	38
20	The long-term prognosis of pneumomediastinum associated with dermatomyositis: a two-centre retrospective cohort study. Rheumatology, 2021, 60, 2288-2295.	1.9	7
21	Predictive value of non-invasive right ventricle to pulmonary circulation coupling in systemic lupus erythematosus patients with pulmonary arterial hypertension. European Heart Journal Cardiovascular Imaging, 2021, 22, 111-118.	1.2	22
22	MicroRNA-320a: an important regulator in the fibrotic process in interstitial lung disease of systemic sclerosis. Arthritis Research and Therapy, 2021, 23, 21.	3.5	14
23	Early Initiation of Anticoagulation Improves the Long-Term Prognosis in Patients With Antiphospholipid Syndrome Associated Portal Vein Thrombosis. Frontiers in Medicine, 2021, 8, 630660.	2.6	1
24	Renal Involvement and HBV Infection Are Common in Chinese Patients With Cryoglobulinemia. Frontiers in Immunology, 2021, 12, 580271.	4.8	3
25	Validation of the REVEAL Prognostic Models in Systemic Lupus Erythematosus-Associated Pulmonary Arterial Hypertension. Frontiers in Medicine, 2021, 8, 618486.	2.6	3
26	"Tree in Bud―in the Chest CT of a Patient with Granulomatosis Polyangiitis. Rheumatology and Immunology Research, 2021, 2, 61-62.	0.8	0
27	Chinese SLE Treatment and Research group (CSTAR) registry 2009–2019: Major clinical characteristics of Chinese patients with systemic lupus erythematosus. Rheumatology and Immunology Research, 2021, 2, 43-47.	0.8	10
28	Clinical characteristics and prognosis of patients with isolated thrombotic vs. obstetric antiphospholipid syndrome: a prospective cohort study. Arthritis Research and Therapy, 2021, 23, 138.	3.5	14
29	Interventricular systolic asynchrony predicts prognosis in patients with systemic sclerosis-associated pulmonary arterial hypertension. Rheumatology, 2021, , .	1.9	3
30	Applications of Protein Microarrays in Biomarker Discovery for Autoimmune Diseases. Frontiers in Immunology, 2021, 12, 645632.	4.8	15
31	Myocardial involvement in idiopathic inflammatory myopathies: a multi-center cross-sectional study in the CRDC-MYO Registry. Clinical Rheumatology, 2021, 40, 4597-4608.	2.2	10
32	Clinical characteristics of adult patients with systemic vasculitis: Data of 1348 patients from a single center. Rheumatology and Immunology Research, 2021, 2, 101-112.	0.8	3
33	Risk of osteonecrosis in systemic lupus erythematosus: An 11-year Chinese single-center cohort study. Lupus, 2021, 30, 1459-1468.	1.6	8
34	Prevalence and risk factors for left ventricular diastolic dysfunction in systemic sclerosis: a multi-center study of CRDC cohort in China. Clinical Rheumatology, 2021, 40, 4589-4596.	2.2	4
35	Screening and identification of potential biomarkers and therapeutic targets for systemic sclerosis-associated interstitial lung disease. Archives of Rheumatology, 2021, 36, 548-559.	0.9	0
36	2020 Chinese expert-based consensus on the diagnosis and treatment of connective tissue disease associated pulmonary arterial hypertension. Rheumatology and Immunology Research, 2021, 2, 63-78.	0.8	0

#	Article	IF	CITATIONS
37	Quality of life in ambulatory pulmonary arterial hypertension in connective tissue diseases and its relationship with risk stratification. Pulmonary Circulation, 2021, 11, 1-8.	1.7	1
38	Platelet distribution width is highly associated with thrombotic events in primary antiphospholipid syndrome. Clinical Rheumatology, 2021, 40, 4581-4588.	2.2	6
39	Effectiveness of iguratimod as monotherapy or combined therapy in patients with rheumatoid arthritis: a systematic review and meta-analysis of RCTs. Journal of Orthopaedic Surgery and Research, 2021, 16, 457.	2.3	3
40	Comparison of Different Test Systems for the Detection of Antiphospholipid Antibodies in a Chinese Cohort. Frontiers in Immunology, 2021, 12, 648881.	4.8	9
41	Diagnosis and treatment directions and research frontiers of systemic lupus erythematosus. Scientia Sinica Vitae, 2021, 51, 887-900.	0.3	0
42	Predicting the Risk of Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus: A Chinese Systemic Lupus Erythematosus Treatment and Research Group Cohort Study. Arthritis and Rheumatology, 2021, 73, 1847-1855.	5.6	18
43	Clinical Characteristics and Prognoses of Patients With Systemic Lupus Erythematosus Hospitalized for Pulmonary Infections. Frontiers in Medicine, 2021, 8, 732681.	2.6	3
44	Evaluation of the Diagnostic Value of Non-criteria Antibodies for Antiphospholipid Syndrome Patients in a Chinese Cohort. Frontiers in Immunology, 2021, 12, 741369.	4.8	10
45	Chinese SLE Treatment and Research Group RegistryÂ(CSTAR)ÂXIII: prevalence and risk factors for chronic scarring alopecia in patients with systemic lupus erythematosus. Arthritis Research and Therapy, 2021, 23, 20.	3.5	1
46	Comparison of relapsing polychondritis patients with and without central nervous system involvement: A retrospective study of 181 patients. International Journal of Immunopathology and Pharmacology, 2021, 35, 205873842110005.	2.1	9
47	Relapse rates and risk factors for unfavorable neurological prognosis of transverse myelitis in systemic lupus erythematosus: A systematic review and meta-analysis. Autoimmunity Reviews, 2021, 21, 102996.	5.8	1
48	The LPS induced pyroptosis exacerbates BMPR2 signaling deficiency to potentiate SLEâ€PAH. FASEB Journal, 2021, 35, e22044.	0.5	15
49	Programmed Cell Death Pathways in the Pathogenesis of Idiopathic Inflammatory Myopathies. Frontiers in Immunology, 2021, 12, 783616.	4.8	10
50	Long-term outcomes of patients with systemic lupus erythematosus: A Multicenter Cohort Study from CSTAR registry. Rheumatology and Immunology Research, 2021, 2, 195-202.	0.8	7
51	The Chinese herb Tripterygium wilfordii Hook F for the treatment of systemic sclerosis-associated interstitial lung disease: data from a Chinese EUSTAR Center. Clinical Rheumatology, 2020, 39, 813-821.	2.2	8
52	Superficial Siderosis and Microbleed Restricted in Cortex Might Be Correlated to Atrophy and Cognitive Decline in Sneddon's Syndrome. Frontiers in Neurology, 2020, 11, 1035.	2.4	1
53	Clinical efficacy and safety of sirolimus in systemic lupus erythematosus: a real-world study and meta-analysis. Therapeutic Advances in Musculoskeletal Disease, 2020, 12, 1759720X2095333.	2.7	23
54	Prevalence, predictors and prognostic benefits of remission achievement in patients with systemic lupus erythematosus: a systematic review. Arthritis Care and Research, 2020, , .	3.4	7

#	Article	IF	CITATIONS
55	Factors Associated With Renal Involvement in Primary Sjögren's Syndrome: A Meta-Analysis. Frontiers in Medicine, 2020, 7, 614482.	2.6	5
56	Predictive Value of Pulmonary Arterial Compliance in Systemic Lupus Erythematosus Patients With Pulmonary Arterial Hypertension. Hypertension, 2020, 76, 1161-1168.	2.7	8
57	Immunoglobulin A Isotype of Antiphospholipid Antibodies Does Not Provide Added Value for the Diagnosis of Antiphospholipid Syndrome in a Chinese Population. Frontiers in Immunology, 2020, 11, 568503.	4.8	9
58	Aberrant expression of cellâ€free nucleosomes in dermatomyositis/polymyositis. Dermatologic Therapy, 2020, 33, e14460.	1.7	3
59	P191â€Chinese systemic lupus erythematosus treatment and research group (CSTAR) registry – subjective well-being in patients with systemic lupus erythematosus. , 2020, , .		0
60	P157â€Update on the real-time collecting system data of SLE treatment and research group (CSTAR) registry: clinical features and remission of patients with systemic lupus erythematosus in China. , 2020, , .		0
61	O27â€Development and validation of a multivariable model for 5-year survival in systemic lupus erythematosus-associated pulmonary arterial hypertension: CSTAR-PAH cohort study. , 2020, , .		0
62	O28â€Characteristics and risk factors of pulmonary embolism in patients with systemic lupus erythematosus: a single-center cohort study. , 2020, , .		3
63	P10â€Antiphospholipid antibodies associated extra-criteria clinical manifestations should not be ignored. , 2020, , .		0
64	P11â€Early efficient anticoagulation improves the long-term prognosis in patients with antiphospholipid syndrome associated portal vein thrombosis. , 2020, , .		0
65	Successful treatment of refractory thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus with combination of plasma exchange and low-dose rituximab. Lupus, 2020, 29, 1961-1967.	1.6	7
66	Association between acute phase reactants, interleukin-6, tumor necrosis factor-α, and disease activity in Takayasu's arteritis patients. Arthritis Research and Therapy, 2020, 22, 285.	3.5	16
67	Etiologies and outcomes of rheumatology patients with acute respiratory failure requiring intensive care: a single-center medical records review study of 259 patients. Clinical Rheumatology, 2020, 39, 3479-3488.	2.2	2
68	Clinical Characteristics of Systemic Lupus Erythematosus with Cirrhosis. Journal of Immunology Research, 2020, 2020, 1-7.	2.2	5
69	Association between comorbidities and extraglandular manifestations in primary Sjögren's syndrome: a multicenter cross-sectional study. Clinical Rheumatology, 2020, 39, 2677-2688.	2.2	13
70	Malignancy and IgG4-related disease: the incidence, related factors and prognosis from a prospective cohort study in China. Scientific Reports, 2020, 10, 4910.	3.3	36
71	JAK Inhibitors: Prospects in Connective Tissue Diseases. Clinical Reviews in Allergy and Immunology, 2020, 59, 334-351.	6.5	83
72	Pulmonary arterial hypertension associated with primary Sjögren's syndrome: a multicentre cohort study from China. European Respiratory Journal, 2020, 56, 1902157.	6.7	27

#	Article	IF	CITATIONS
73	Clinical features of transverse myelitis associated with systemic lupus erythematosus. Lupus, 2020, 29, 389-397.	1.6	22
74	Systemic lupus erythematosus–associated diffuse alveolar hemorrhage: a single-center, matched case–control study in China. Lupus, 2020, 29, 795-803.	1.6	22
75	Characteristics and long-term outcomes of patients with lupus-related protein-losing enteropathy: A retrospective study. Rheumatology and Immunology Research, 2020, 1, 47-52.	0.8	2
76	Abstract WP476: Remarkable Hemorrhagic Imaging Manifestations Might Be Responsible for the Prominent Atrophy and Cognitive Decline in Sneddon Syndrome. Stroke, 2020, 51, .	2.0	0
77	Characteristics and risk factors of pulmonary embolism in patients with systemic lupus erythematosus: a case control study. Clinical and Experimental Rheumatology, 2020, 38, 940-948.	0.8	2
78	Clinical features of immunoglobulin G4-related disease with central nervous system involvement: an analysis of 15 cases. Clinical and Experimental Rheumatology, 2020, 38, 626-632.	0.8	5
79	Hepatic Infarction Caused by Antiphospholipid Syndrome Secondary to Systemic Lupus Erythematosus. Journal of Rheumatology, 2019, 46, 755-756.	2.0	5
80	Early short‑term ivabradine treatment in new‑onset acute systolic heart failure and sinus tachycardia patients with inflammatory rheumatic disease. Experimental and Therapeutic Medicine, 2019, 18, 305-311.	1.8	3
81	Identification of 6 dermatomyositis subgroups using principal component analysisâ€based cluster analysis. International Journal of Rheumatic Diseases, 2019, 22, 1383-1392.	1.9	5
82	Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: the experience from a single centre. Annals of the Rheumatic Diseases, 2019, 78, 1441-1443.	0.9	43
83	Serum KL-6 is associated with the severity of interstitial lung disease in Chinese patients with polymyositis and dermatomyositis. Clinical Rheumatology, 2019, 38, 2181-2187.	2.2	21
84	Pulmonary arterial hypertension in systemic lupus erythematosus based on a CSTARâ€₽AH study: Baseline characteristics and risk factors. International Journal of Rheumatic Diseases, 2019, 22, 921-928.	1.9	26
85	220â€Clinical characteristics and remission of patients with systemic lupus erythematosus in china: results from SLE treatment and research group (CSTAR) registry with a real-time collecting system. , 2019, , .		3
86	OP0062â€IDENTIFICATION OF SIX DERMATOMYOSITIS SUBGROUPS USING PRINCIPAL COMPONENT ANALYSIS-BASED CLUSTER ANALYSIS. , 2019, , .		0
87	247â€New organ involvement development during follow-up of patients with systemic lupus erythematosus in China: a Multi-center cohort study from CSTAR registry. , 2019, , .		0
88	33â€Composite goals plus inflammation: further risk assessment for systemic lupus erythematosus associated pulmonary arterial hypertension in CSTAR-PAH cohort. , 2019, , .		0
89	Association between lymphocyte subsets and cytomegalovirus infection status among patients with systemic lupus erythematosus. Medicine (United States), 2019, 98, e16997.	1.0	16
90	Red blood cell distribution width as a potential predictor of survival of pulmonary arterial hypertension associated with primary Sjogren's syndrome: a retrospective cohort study. Clinical Rheumatology, 2019, 38, 477-485.	2.2	10

#	Article	IF	CITATIONS
91	Inflammation in SLE-PAH: good news or not?. Annals of the Rheumatic Diseases, 2019, 78, e135-e135.	0.9	10
92	Long-term prognosis of patients with systemic lupus erythematosus-associated pulmonary arterial hypertension: CSTAR-PAH cohort study. European Respiratory Journal, 2019, 53, 1800081.	6.7	49
93	Right Ventricular Function is Associated With Quality of Life in Patients With Systemic Lupus Erythematosus Associated Pulmonary Arterial Hypertension. Heart Lung and Circulation, 2019, 28, 1655-1663.	0.4	9
94	Cysteine-rich protein 61 as a novel biomarker in systemic lupus erythematosus-associated pulmonary arterial hypertension. Clinical and Experimental Rheumatology, 2019, 37, 623-632.	0.8	5
95	Characteristics and risk factors of pulmonary arterial hypertension in patients with primary Sjögren's syndrome. International Journal of Rheumatic Diseases, 2018, 21, 1068-1075.	1.9	21
96	Antibodies to phosphatidylserine/prothrombin (aPS/PT) enhanced the diagnostic performance in Chinese patients with antiphospholipid syndrome. Clinical Chemistry and Laboratory Medicine, 2018, 56, 939-946.	2.3	15
97	Chinese SLE Treatment and Research Group (CSTAR) registry:VIII. Influence of socioeconomic and geographical variables on disease phenotype and activity in Chinese patients with <scp>SLE</scp> . International Journal of Rheumatic Diseases, 2018, 21, 716-724.	1.9	13
98	Red blood cell distribution width as a related factor of pulmonary arterial hypertension in patients with systemic sclerosis. Clinical Rheumatology, 2018, 37, 979-985.	2.2	19
99	High-Dose Glucocorticoid Treatment Does Not Induce Severe Hyperglycemia in Young Patients with Autoimmune Diseases by Cgms. Endocrine Practice, 2018, 24, 60-68.	2.1	0
100	Curative resolution of chronic thromboembolic pulmonary hypertension with pulmonary thromboendarterectomy in primary antiphospholipid syndrome. Medicine (United States), 2018, 97, e12710.	1.0	0
101	Is it possible to apply the treat-to-target strategy in primary Sjögren's syndrome-associated pulmonary arterial hypertension?. Clinical Rheumatology, 2018, 37, 2989-2998.	2.2	5
102	The renal artery is involved in Chinese Takayasu's arteritis patients. Kidney International, 2018, 93, 245-251.	5.2	24
103	Chinese lupus treatment and research group (CSTAR) registry: X. family history in relation to lupus clinical and immunological manifestations. Clinical and Experimental Rheumatology, 2018, 36, 81-87.	0.8	1
104	Evaluation of the clinical relevance of anti-annexin-A5 antibodies in Chinese patients with antiphospholipid syndrome. Clinical Rheumatology, 2017, 36, 407-412.	2.2	14
105	Clinical characteristics and survival of pulmonary arterial hypertension associated with three major connective tissue diseases: A cohort study in China. International Journal of Cardiology, 2017, 236, 432-437.	1.7	81
106	Successful treatment of type B insulin resistance with mixed connective tissue disease by pulse glucocorticoids and cyclophosphamide. Journal of Diabetes Investigation, 2017, 8, 626-628.	2.4	10
107	Flares in Chinese systemic lupus erythematosus patients: a 6-year follow-up study. Clinical Rheumatology, 2017, 36, 2727-2732.	2.2	9
108	Cerebroretinal microangiopathy with calcifications and cysts. Medicine (United States), 2017, 96, e5545.	1.0	1

#	Article	IF	CITATIONS
109	Clinical Characteristics of Heart Involvement in Chinese Patients with Takayasu Arteritis. Journal of Rheumatology, 2017, 44, 1867-1874.	2.0	30
110	Response to letter "Clinical characteristics and survival of pulmonary arterial hypertension associated with three major connective tissue diseases: Methodological issues― International Journal of Cardiology, 2017, 249, 418.	1.7	1
111	The clinical characteristics of Chinese Takayasu's arteritis patients: a retrospective study of 411 patients over 24 years. Arthritis Research and Therapy, 2017, 19, 107.	3.5	41
112	Clinical performance of antibodies to prothrombin and thrombin in Chinese patients with antiphospholipid syndrome: potential interest in discriminating patients with thrombotic events and non-thrombotic events. Rheumatology International, 2017, 37, 579-584.	3.0	7
113	The efficacy of tocilizumab for the treatment of Chinese Takayasu's arteritis. Clinical and Experimental Rheumatology, 2017, 35 Suppl 103, 171-175.	0.8	13
114	Baseline Characteristics and Risk Factors of Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus Patients. Medicine (United States), 2016, 95, e2761.	1.0	59
115	The efficacy of Mycophenolate mofetil for the treatment of Chinese Takayasu's arteritis. Scientific Reports, 2016, 6, 38687.	3.3	20
116	Cause of death in Chinese Takayasu arteritis patients. Medicine (United States), 2016, 95, e4069.	1.0	41
117	Evaluation of the diagnostic potential of antibodies to beta2-glycoprotein 1 domain 1 in Chinese patients with antiphospholipid syndrome. Scientific Reports, 2016, 6, 23839.	3.3	23
118	The Role of Anti–U1 RNP Positivity in Predicting Survival in Patients With Connective Tissue Disease–Associated Pulmonary Arterial Hypertension: Angel or Demon? Comment on the Article by Sobanski et al. Arthritis and Rheumatology, 2016, 68, 1788-1789.	5.6	8
119	Survival and prognostic factors of systemic lupus erythematosus-associated pulmonary arterial hypertension: A PRISMA-compliant systematic review and meta-analysis. Autoimmunity Reviews, 2016, 15, 250-257.	5.8	45
120	Predictors of health-related quality of life in patients with systemic lupus erythematosus associated pulmonary arterial hypertension. Clinical and Experimental Rheumatology, 2016, 34, 291-5.	0.8	7
121	ANCA-Associated Systemic Vasculitis Presenting With Hypertrophic Spinal Pachymeningitis. Medicine (United States), 2015, 94, e2053.	1.0	18
122	Long-Term Survival and Death Causes of Systemic Lupus Erythematosus in China. Medicine (United) Tj ETQq0 0 (D rgBT /Ov	erlock 10 Tf 81
123	Chinese Systemic Lupus Erythematosus Treatment and Research Group Registry VI: Effect of Cigarette Smoking on the Clinical Phenotype of Chinese Patients with Systemic Lupus Erythematosus. PLoS ONE, 2015, 10, e0134451.	2.5	21
124	Related factors of fetal loss in Chinese women with systemic lupus erythematosus: data from Chinese SLE Treatment and Research Group registry IV. International Journal of Rheumatic Diseases, 2015, 18, 654-660.	1.9	13
125	Clinical Analysis of 61 Systemic Lupus Erythematosus Patients With Intestinal Pseudo-Obstruction and/or Ureterohydronephrosis. Medicine (United States), 2015, 94, e419.	1.0	16

126	Chinese SLE Treatment and Research Group Registry: III. Association of Autoantibodies with Clinical Manifestations in Chinese Patients with Systemic Lupus Erythematosus. Journal of Immunology	2.2	40
	Research, 2014, 2014, 1-8.		

#	Article	IF	CITATIONS
127	Sex Differences in Clinical Characteristics and Prognosis in Primary Thrombotic Antiphospholipid Syndrome. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	1